ArticleTrials2025
Intrawound vancomycin powder for prevention of surgical site infections after open instrumented posterior spinal fusion (VANCO Trial)-methodology of a randomized, controlled, multicenter study.
Article in Trials, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT04017468 (Suprafascial Vancomycin Powder for Prevention of Surgical Site Infections After Instrumented Posterior Spinal Fusion), which is not on this map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Suprafascial Vancomycin Powder for Prevention of Surgical Site Infections After Instrumented Posterior Spinal Fusion
Who cites it
2 citing papers in PubMed.
- Intrawound Vancomycin Powder in Surgical Site Infection Prophylaxis: A Comprehensive Review of Mechanisms, Efficacy, Safety, and Clinical Controversies.Advances in therapy · 2026Review
- Modulation of Surgical Site Infection Risk in Spinal and Thoracic Surgeries Through Operative Parameters: A Narrative Review.Journal of clinical medicine · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
backgroundSurgical site infections (SSIs) after instrumented spine fusion surgery may occur in up to 12% of cases and lead to increased morbidity, mortality, and healthcare costs. Numerous retrospective studies suggest the use of intrawound vancomycin powder in spine surgery to be protective against SSIs. The use of intrawound vancomycin powder is controversial, and there is a paucity of well-designed prospective trials evaluating its safety and efficacy in spine surgery. The objective of the VANCO Trial is to evaluate the safety and efficacy of intrawound vancomycin powder in open instrumented spine fusion surgery to prevent SSIs.
methodsThe VANCO Trial is a multicenter, 1:1 randomized superiority trial with a total of 7 recruiting spine institutions in Switzerland. Adult patients scheduled for an open spinal fusion procedure will be screened for eligibility. Randomization of participants will take place intraoperatively before wound closure. Patients randomized into the treatment arm will receive 1-2 g of vancomycin powder (depending on length of skin incision: ≤ 20 cm vs. > 20 cm), which will be administered above the closed muscle fascia (suprafascially-subcutaneously) before wound closure. The main outcome and measure is the rate of superficial and deep SSIs within 90 days following surgery. DISCUSSION: The VANCO Trial is one of the first clinical trials to evaluate the safety and efficacy of intrawound vancomycin powder in a selected spine surgery population. Routine administration of intrawound vancomycin powder in selected spine surgery patients could fundamentally advance international standards for reducing SSIs.
trial registrationClinicalTrials.gov NCT04017468.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.